TCRX RSI Chart
Last 7 days
16.0%
Last 30 days
32.9%
Last 90 days
32.3%
Trailing 12 Months
173.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 17.3M | 16.4M | 16.9M | 21.0M |
2022 | 11.1M | 12.3M | 13.3M | 13.5M |
2021 | 3.3M | 5.6M | 7.9M | 10.1M |
2020 | 0 | 0 | 0 | 1.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 19, 2023 | barberich timothy j | bought | 1,575 | 4.9685 | 317 | - |
Dec 18, 2023 | barberich timothy j | bought | 140,881 | 4.8866 | 28,830 | - |
Dec 14, 2023 | klencke barbara | bought | 25,400 | 5.08 | 5,000 | - |
Jun 02, 2023 | barberich timothy j | bought | 99,563 | 2.6284 | 37,880 | - |
May 31, 2023 | lynx1 capital management lp | sold | -38,804 | 2.51977 | -15,400 | - |
May 31, 2023 | lynx1 capital management lp | sold | -25,148 | 2.5148 | -10,000 | - |
Dec 28, 2022 | silver brian m. | bought | 4,941 | 1.5646 | 3,158 | chief financial officer |
Dec 27, 2022 | silver brian m. | bought | 4,276 | 1.5047 | 2,842 | chief financial officer |
May 18, 2022 | southwell david p | bought | 89,821 | 3.59284 | 25,000 | chief executive officer |
May 11, 2022 | baker bros. advisors lp | bought | 51,349 | 1.9853 | 25,865 | - |
Which funds bought or sold TCRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 83.13 | 728,360 | 1,215,880 | -% |
May 15, 2024 | Lynx1 Capital Management LP | unchanged | - | 11,023,900 | 41,483,300 | 10.75% |
May 15, 2024 | BVF INC/IL | unchanged | - | 6,307,790 | 23,736,400 | 0.65% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | added | 759 | 1,889,010 | 2,065,580 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 90,770 | 90,770 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -28.31 | -12,187 | 502,602 | 0.01% |
May 15, 2024 | Walleye Capital LLC | added | 195 | 313,035 | 416,675 | -% |
May 15, 2024 | STATE STREET CORP | added | 120 | 715,687 | 1,071,900 | -% |
May 15, 2024 | Point72 Asia (Singapore) Pte. Ltd. | new | - | 156,704 | 156,704 | 0.04% |
May 15, 2024 | Man Group plc | added | 53.42 | 320,182 | 614,072 | -% |
Unveiling TScan Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to TScan Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
TScan Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Revenue | -100.0% | - | 7,211 | 3,887 | 3,148 | 6,803 | 3,095 | 3,363 | 4,056 | 3,021 | 2,854 | 2,412 | 2,848 | 2,027 | 1,159 | 290 |
Operating Expenses | 11.8% | 31,939 | 28,568 | 28,635 | 27,758 | 29,546 | 21,744 | 19,941 | 19,302 | 19,184 | 17,056 | 18,254 | 13,527 | 9,945 | - | 7,461 |
S&GA Expenses | -100.0% | - | 6,162 | 5,894 | 6,531 | 7,767 | 6,140 | 4,910 | 4,808 | 4,494 | 4,448 | 4,048 | 2,726 | 2,606 | - | 1,648 |
R&D Expenses | 10.9% | 24,857 | 22,406 | 22,741 | 21,227 | 21,779 | 15,604 | 15,031 | 14,494 | 14,690 | 12,608 | 14,206 | 10,801 | 7,339 | - | 5,813 |
Interest Expenses | 12.6% | 959 | 852 | 982 | 969 | 956 | - | 201 | - | - | - | - | - | - | - | - |
Net Income | -53.5% | -30,100 | -19,613 | -22,997 | -24,045 | -22,563 | -18,723 | -16,245 | -15,097 | -16,156 | -14,200 | -15,839 | -10,674 | -7,912 | - | -7,170 |
Net Income Margin | -8.4% | -4.60* | -4.24* | -5.22* | -4.97* | -4.19* | -4.89* | -4.64* | -4.97* | -5.11* | -4.79* | -3.32* | -4.65* | -7.80* | -24.08* | - |
Free Cashflow | -23.7% | -29,972 | -24,235 | 6,598 | -22,442 | -24,425 | -17,387 | -17,426 | -15,260 | -20,655 | -16,591 | -14,493 | -14,618 | -12,916 | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -11.5% | 241 | 272 | 291 | 317 | 174 | 199 | 165 | 152 | 168 | 188 | 205 | 130 | 50.00 |
Current Assets | -15.2% | 165 | 194 | 218 | 242 | 101 | 124 | 141 | 129 | 146 | 166 | 187 | 110 | 36.00 |
Cash Equivalents | 9.1% | 146 | 133 | 155 | 209 | 96.00 | 120 | 137 | 126 | 141 | 166 | 182 | 106 | 35.00 |
Net PPE | -7.0% | 7.00 | 8.00 | 9.00 | 8.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 12.00 | 11.00 | 10.00 | 6.00 |
Liabilities | -2.8% | 118 | 121 | 122 | 126 | 96.00 | 100 | 49.00 | 21.00 | 23.00 | 27.00 | 31.00 | 31.00 | 33.00 |
Current Liabilities | 5.6% | 31.00 | 30.00 | 33.00 | 35.00 | 14.00 | 17.00 | 17.00 | 17.00 | 18.00 | 21.00 | 23.00 | 21.00 | 17.00 |
Long Term Debt | -12.2% | 23.00 | 27.00 | 29.00 | 30.00 | 30.00 | 29.00 | 29.00 | - | - | - | - | - | - |
LT Debt, Current | 103.1% | 7.00 | 3.00 | 1.00 | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 27.00 | 29.00 | 30.00 | 30.00 | 29.00 | 29.00 | - | - | - | - | - | - |
Shareholder's Equity | -18.5% | 123 | 151 | 169 | 191 | 78.00 | 99.00 | 117 | 132 | 146 | 161 | 174 | - | - |
Retained Earnings | -12.2% | -277 | -247 | -228 | -205 | -180 | -158 | -139 | -123 | -108 | -92.16 | -77.96 | -62.12 | -43.53 |
Additional Paid-In Capital | 0.6% | 401 | 398 | 397 | 396 | 259 | 258 | 256 | 255 | 254 | 253 | 252 | 2.00 | 1.00 |
Shares Outstanding | 44.6% | 95.00 | 66.00 | 56.00 | 47.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 12.00 | 8.00 | 1.00 | 1.00 |
Float | - | - | - | - | 74.00 | - | - | - | 49,197 | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -23.1% | -29,267 | -23,766 | 8,017 | -22,022 | -23,587 | -16,010 | -17,002 | -13,367 | -20,124 | -14,380 | -13,640 | -10,700 | -9,957 | - | - | - |
Share Based Compensation | 32.3% | 1,984 | 1,500 | 1,341 | 1,220 | 1,147 | 1,297 | 1,246 | 1,024 | 984 | 784 | 885 | 503 | 344 | - | - | - |
Cashflow From Investing | 1790.4% | 36,163 | 1,913 | -61,414 | -420 | -838 | -1,377 | -424 | -1,893 | -531 | -2,211 | -853 | -3,918 | -2,959 | - | - | - |
Cashflow From Financing | 1257.9% | 258 | 19.00 | -252 | - | - | 108 | 29,129 | 31.00 | 88.00 | 120 | 90,608 | -686 | 99,626 | - | - | - |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | ||
Collaboration and license revenue | $ 566 | $ 6,803 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Collaboration and license revenue | Collaboration and license revenue |
Operating expenses: | ||
Research and development | $ 24,857 | $ 21,779 |
General and administrative | 7,082 | 7,767 |
Total operating expenses | 31,939 | 29,546 |
Loss from operations | (31,373) | (22,743) |
Other (expense) income: | ||
Interest and other income, net | 2,190 | 1,136 |
Interest expense | (959) | (956) |
Total other income | 1,231 | 180 |
Net loss | $ (30,142) | $ (22,563) |
Net loss per share, basic | $ (0.32) | $ (0.93) |
Net loss per share, diluted | $ (0.32) | $ (0.93) |
Weighted average common shares outstanding- basic | 94,875,893 | 24,225,954 |
Weighted average common shares outstanding-diluted | 94,875,893 | 24,225,954 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 140,513 | $ 133,359 |
Marketable securities | 22,270 | 58,685 |
Prepaid expenses and other current assets | 1,938 | 2,193 |
Total current assets | 164,721 | 194,237 |
Property and equipment, net | 7,201 | 7,742 |
Right-of-use assets | 62,232 | 63,492 |
Restricted cash | 5,031 | 5,031 |
Long-term deposit and other assets | 1,647 | 1,647 |
Total assets | 240,832 | 272,149 |
Current liabilities: | ||
Accounts payable | 2,123 | 2,374 |
Accrued expenses and other current liabilities | 8,786 | 10,716 |
Operating lease liability, current portion | 3,338 | 3,246 |
Deferred revenue, current portion | 10,435 | 10,137 |
Current portion of long-term debt | 6,797 | 3,347 |
Total current liabilities | 31,479 | 29,820 |
Deferred revenue, net of current portion | 4,758 | 5,622 |
Operating lease liability, net of current portion | 58,179 | 59,140 |
Long-term debt and accrued interest | 23,449 | 26,700 |
Total liabilities | 117,865 | 121,282 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 400,701 | 398,459 |
Accumulated deficit | (277,739) | (247,597) |
Total stockholders' equity | 122,967 | 150,867 |
Total liabilities and stockholders' equity | 240,832 | 272,149 |
Voting Common Stock | ||
Stockholders' equity: | ||
Common stock | 4 | 4 |
Non-voting Common Stock | ||
Stockholders' equity: | ||
Common stock | $ 1 | $ 1 |